DiaMedica Therapeutics (DMAC) Operating Leases (2019 - 2026)

DiaMedica Therapeutics (DMAC) has reported Operating Leases for 8 consecutive years, with $176000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 35.29% year-over-year to $176000.0; the trailing twelve-month figure through Jun 2026 stood at $176000.0 (down 35.29% YoY), and the FY2025 full-year result was $124000.0, down 44.89% from the prior year.
• Operating Leases fell to $176000.0 in Q2 2026 per DMAC's latest filing, from $200000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $459000.0 in Q3 2022 and bottomed at $11000.0 in Q2 2022.
• Historically, Operating Leases has averaged $284388.9 across 5 years, with a median of $305000.0 in 2023.
• The widest YoY moves for Operating Leases: up 13100.0% in 2022, down 85.33% in 2022.
• Over 5 years, Operating Leases stood at $396000.0 in 2022, then decreased by 20.2% to $316000.0 in 2023, then decreased by 28.8% to $225000.0 in 2024, then tumbled by 44.89% to $124000.0 in 2025, then soared by 41.94% to $176000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $176000.0, $200000.0, and $124000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.